|
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455). |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD Oncology; Novartis; Roche; Takeda |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - CSL Behring |
|
|
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Ipsen; Novartis; PharmaMar |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; MSD; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Roche |
Research Funding - Boehringer Ingelheim (Inst); MSD (Inst); Roche (Inst) |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche; SERVIER |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Celgene; Janssen |
|
|
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD Oncology; Novartis; Roche |
|
|
Employment - Boehringer Ingelheim |
|
|
Employment - Boehringer Ingelheim |
Patents, Royalties, Other Intellectual Property - Boehringer Ingelheim (Inst) |